Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma

DB Zhen; A Coveler; Silvia Zanon; M Reni; EG Chiorean

doi:10.1053/j.seminoncol.2018.05.004

Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma

DB Zhen, A Coveler, Silvia Zanon, M Reni, EG Chiorean

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains a deadly disease with few effective treatment options. Our knowledge of molecular alterations in PDAC has significantly grown and helped identify new therapeutic targets. The success of immune checkpoint inhibition in mismatch repair deficient tumors, PARP inhibitors for tumors with DNA repair defects, and targeting hyaluronan with PEGPH20 in patients with high expressing (hyaluronan-high) tumors are examples of promising biomarker-driven therapies. We review the major biological mechanisms in PDAC and discuss current and future directions for molecularly targeted therapies in this disease. © 2018 Elsevier Inc.

Original language	English
Pages (from-to)	107-115
Number of pages	9
Journal	Seminars in Oncology
Volume	45
Issue number	3
DOIs	https://doi.org/10.1053/j.seminoncol.2018.05.004
Publication status	Published - 2018

Access to Document

10.1053/j.seminoncol.2018.05.004

http://www.scopus.com/inward/record.url?scp=85055730320&partnerID=8YFLogxK

Cite this

@article{50a0f62a53ee4261b380b082a9d8b61b,

title = "Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma",

abstract = "Pancreatic ductal adenocarcinoma (PDAC) remains a deadly disease with few effective treatment options. Our knowledge of molecular alterations in PDAC has significantly grown and helped identify new therapeutic targets. The success of immune checkpoint inhibition in mismatch repair deficient tumors, PARP inhibitors for tumors with DNA repair defects, and targeting hyaluronan with PEGPH20 in patients with high expressing (hyaluronan-high) tumors are examples of promising biomarker-driven therapies. We review the major biological mechanisms in PDAC and discuss current and future directions for molecularly targeted therapies in this disease. {\textcopyright} 2018 Elsevier Inc.",

author = "DB Zhen and A Coveler and Silvia Zanon and M Reni and EG Chiorean",

year = "2018",

doi = "10.1053/j.seminoncol.2018.05.004",

language = "English",

volume = "45",

pages = "107--115",

journal = "Seminars in Oncology",

issn = "0093-7754",

publisher = "W.B. Saunders Ltd",

number = "3",

}

TY - JOUR

T1 - Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma

AU - Zhen, DB

AU - Coveler, A

AU - Zanon, Silvia

AU - Reni, M

AU - Chiorean, EG

PY - 2018

Y1 - 2018

N2 - Pancreatic ductal adenocarcinoma (PDAC) remains a deadly disease with few effective treatment options. Our knowledge of molecular alterations in PDAC has significantly grown and helped identify new therapeutic targets. The success of immune checkpoint inhibition in mismatch repair deficient tumors, PARP inhibitors for tumors with DNA repair defects, and targeting hyaluronan with PEGPH20 in patients with high expressing (hyaluronan-high) tumors are examples of promising biomarker-driven therapies. We review the major biological mechanisms in PDAC and discuss current and future directions for molecularly targeted therapies in this disease. © 2018 Elsevier Inc.

AB - Pancreatic ductal adenocarcinoma (PDAC) remains a deadly disease with few effective treatment options. Our knowledge of molecular alterations in PDAC has significantly grown and helped identify new therapeutic targets. The success of immune checkpoint inhibition in mismatch repair deficient tumors, PARP inhibitors for tumors with DNA repair defects, and targeting hyaluronan with PEGPH20 in patients with high expressing (hyaluronan-high) tumors are examples of promising biomarker-driven therapies. We review the major biological mechanisms in PDAC and discuss current and future directions for molecularly targeted therapies in this disease. © 2018 Elsevier Inc.

U2 - 10.1053/j.seminoncol.2018.05.004

DO - 10.1053/j.seminoncol.2018.05.004

M3 - Article

SN - 0093-7754

VL - 45

SP - 107

EP - 115

JO - Seminars in Oncology

JF - Seminars in Oncology

IS - 3

ER -

Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma

Abstract

Access to Document

Fingerprint

Cite this